Junevity Expands Seed Funding to $20 Million to Advance Cell Reprogramming Therapeutics
Junevity, a San Francisco–based biotechnology company focused on developing transformative siRNA (small interfering RNA) therapeutics to extend human healthspan and lifespan, has expanded its seed financing to $20 million following an additional capital infusion that builds on its initial seed round. The company’s mission is to leverage its proprietary RESET platform — which combines human disease omics, genetic linkages, machine learning and siRNA screening — to identify and silence key transcription factors that drive cellular dysfunction in age‑related diseases and metabolic disorders. New funding will support Junevity’s lead therapeutic candidate, JUN_01, through IND‑enabling studies and toward first‑in‑human clinical trials expected in the second half of 2026.
Junevity was founded in 2023 by a team of scientists and entrepreneurs with deep expertise in aging biology, artificial intelligence and drug development. The company’s RESET platform identifies transcription factors — master regulators of gene expression — that have previously been considered “undruggable.” By repressing these targets with siRNA, Junevity aims to reset diseased cells toward healthier states, addressing underlying dysfunction in conditions such as type 2 diabetes, obesity, frailty and ultimately neurodegenerative diseases.
The expanded seed round was led by Goldcrest Capital and Godfrey Capital, two investors aligned with Junevity’s long-term vision of bringing next-generation cell reprogramming therapeutics to patients. These backers initially supported the company’s $10 million seed financing and have continued their commitment, demonstrating confidence in the scientific foundation and commercial potential of the RESET platform. Junevity’s leadership team underscores that this expanded capital will expedite progress on JUN_01, its first siRNA candidate designed to reprogram metabolism toward healthier states, and help scale additional programs in metabolic disease and age‑related disorders.
Junevity’s CEO and co‑founder, Dr. John Hoekman, has articulated a clear path forward for the company: advancing JUN_01 through regulatory‑enabling work and into early clinical evaluation. In preclinical models, JUN_01 has demonstrated promising results, such as reductions in blood glucose, improved insulin sensitivity, robust weight loss, maintenance of lean mass and a dosing profile that could be administered as infrequently as once every six months. These characteristics suggest potential advantages over existing therapeutic approaches and could address critical unmet needs in metabolic disease treatment.
The company’s expanded funding arrives amid growing interest in therapeutics that go beyond symptom management to address fundamental biological processes underlying age‑related disease. Junevity’s approach seeks to “reset” cellular transcription patterns that deteriorate with age and disease progression, potentially altering the trajectory of conditions that impact millions worldwide. Researchers and industry leaders have noted that the integration of large-scale human data with AI‑driven target discovery could accelerate the development of innovative siRNA drugs that modulate complex disease biology.
Junevity’s co‑founder and Chief Scientific Officer, Dr. Janine Sengstack, developed the foundational science behind the RESET platform during her work at UCSF, where her research demonstrated that repressing specific transcription factors could restore diseased cells toward a healthier state. This foundational insight catalyzed the creation of Junevity and underpins the company’s broader strategy of identifying novel targets and siRNA therapeutics capable of reversing cellular dysfunction across multiple disease areas.
The technology licensed from UCSF positions Junevity to build a pipeline of siRNA candidates, with JUN_01 at the forefront targeting metabolic dysfunction and subsequent candidates exploring neurodegeneration and other age-associated conditions. By expanding its seed financing, Junevity is better equipped to invest in manufacturing scale-up, regulatory strategy and the expansion of its scientific team to support multiple clinical programs.
Industry observers have noted that the biopharmaceutical landscape is increasingly receptive to therapies that leverage gene-silencing technologies such as siRNA, particularly as delivery mechanisms and target identification tools have matured. Junevity’s expanded funding reflects this broader momentum, as well as investor belief in the company’s ability to translate its scientific insights into real-world therapies that could change the way chronic diseases are treated.
Looking ahead, Junevity aims to begin first-in-human studies for JUN_01 in the second half of 2026, a pivotal next step in validating its siRNA cell reprogramming approach in metabolic disease. With this expanded seed round, strategic investor support from Goldcrest Capital and Godfrey Capital, and a platform rooted in cutting-edge science, Junevity is poised to push forward on its goal of extending healthspan and lifespan by tackling the root causes of cellular aging and disease.
